AU2022400921A1 - Ccr8 antigen binding unit and uses thereof - Google Patents

Ccr8 antigen binding unit and uses thereof Download PDF

Info

Publication number
AU2022400921A1
AU2022400921A1 AU2022400921A AU2022400921A AU2022400921A1 AU 2022400921 A1 AU2022400921 A1 AU 2022400921A1 AU 2022400921 A AU2022400921 A AU 2022400921A AU 2022400921 A AU2022400921 A AU 2022400921A AU 2022400921 A1 AU2022400921 A1 AU 2022400921A1
Authority
AU
Australia
Prior art keywords
seq
antigen binding
binding unit
cells
ccr8
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022400921A
Other languages
English (en)
Inventor
David BELLOVIN
Min Chen
Xinchuan DAI
Lishan Kang
Shou LI
Hongshui LIU
Wenhua SHI
Bing WAN
Lina Wang
Shang YIN
Jing Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zai Lab Shanghai Co Ltd
Zai Lab US LLC
Original Assignee
Zai Lab Shanghai Co Ltd
Zai Lab US LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zai Lab Shanghai Co Ltd, Zai Lab US LLC filed Critical Zai Lab Shanghai Co Ltd
Publication of AU2022400921A1 publication Critical patent/AU2022400921A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2022400921A 2021-12-02 2022-12-02 Ccr8 antigen binding unit and uses thereof Pending AU2022400921A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/134930 2021-12-02
CN2021134930 2021-12-02
PCT/CN2022/136276 WO2023098888A1 (en) 2021-12-02 2022-12-02 Ccr8 antigen binding unit and uses thereof

Publications (1)

Publication Number Publication Date
AU2022400921A1 true AU2022400921A1 (en) 2024-06-27

Family

ID=86611552

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022400921A Pending AU2022400921A1 (en) 2021-12-02 2022-12-02 Ccr8 antigen binding unit and uses thereof

Country Status (11)

Country Link
US (1) US20250034266A1 (cg-RX-API-DMAC7.html)
EP (1) EP4441098A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024541680A (cg-RX-API-DMAC7.html)
KR (1) KR20240112929A (cg-RX-API-DMAC7.html)
CN (1) CN119072494A (cg-RX-API-DMAC7.html)
AU (1) AU2022400921A1 (cg-RX-API-DMAC7.html)
CA (1) CA3239784A1 (cg-RX-API-DMAC7.html)
IL (1) IL313177A (cg-RX-API-DMAC7.html)
MX (1) MX2024006743A (cg-RX-API-DMAC7.html)
TW (1) TW202342533A (cg-RX-API-DMAC7.html)
WO (1) WO2023098888A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
TW202511293A (zh) * 2023-05-23 2025-03-16 中國大陸商再鼎醫藥(上海)有限公司 包含抗ccr8抗體的製劑及其用途
WO2024248037A1 (ja) 2023-05-30 2024-12-05 塩野義製薬株式会社 Ccr8を抗原として認識する二重特異性抗体
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗fap-light融合蛋白及其用途
CN120230205A (zh) * 2023-12-29 2025-07-01 苏州泽璟生物制药股份有限公司 包含ccr8抗原结合结构域的多特异性抗体
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
WO2025186043A1 (en) 2024-03-06 2025-09-12 Bayer Aktiengesellschaft Pharmaceutical formulation for anti-ccr8 antibodies
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
US10087259B1 (en) * 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
CN110835371A (zh) * 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8单克隆抗体及其应用
BR112021011431A2 (pt) * 2018-12-27 2021-11-23 Univ Osaka Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit
TWI890283B (zh) * 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
AU2021244200A1 (en) * 2020-03-23 2022-11-24 Bristol-Myers Squibb Company Anti-CCR8 antibodies for treating cancer
TW202216771A (zh) * 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體

Also Published As

Publication number Publication date
US20250034266A1 (en) 2025-01-30
EP4441098A1 (en) 2024-10-09
WO2023098888A1 (en) 2023-06-08
TW202342533A (zh) 2023-11-01
CA3239784A1 (en) 2023-06-08
IL313177A (en) 2024-07-01
JP2024541680A (ja) 2024-11-08
EP4441098A4 (en) 2026-03-04
MX2024006743A (es) 2024-08-27
KR20240112929A (ko) 2024-07-19
CN119072494A (zh) 2024-12-03

Similar Documents

Publication Publication Date Title
WO2023098888A1 (en) Ccr8 antigen binding unit and uses thereof
US11267885B2 (en) CD47 antigen binding unit and uses thereof
JP7856702B2 (ja) Cd38を特異的に結合する抗体による免疫調節及び固形腫瘍の治療
JP5039027B2 (ja) 結腸癌および膵臓癌のための、組換え型モノクローナル抗体および対応する抗原
KR20210003808A (ko) 항-클라우딘 18.2 항체 및 이의 사용
JP2020504095A (ja) 抗PD−L1抗体との組み合わせのための抗Tim−3抗体
JP2013531655A (ja) S100a4抗体およびその治療上の使用
RU2694903C1 (ru) Антитела к CD43 и их применение для лечения рака
EP3404040B1 (en) Anti-myl9 antibody
WO2008153636A1 (en) Phospho-specific antibodies to p13k regulatory subunit and uses thereof
US9163080B2 (en) Anti-single-chain type IV collagen polypeptide antibody, pharmaceutical drug, diagnostic, preventive, or therapeutic drug for tumour containing the antibody
HK40120943A (en) Ccr8 antigen binding unit and uses thereof
RU2780859C2 (ru) Cd47-антигенсвязывающая единица и ее применение
US20240174741A1 (en) Il-38-specific antibodies
US20130302341A1 (en) Therapeutic and diagnostic applications targeting tnk-1
KR20240176948A (ko) 소세포폐암 진단 및 치료를 위한 타겟으로서 클라우딘-3의 용도
HK40015810A (en) Cd47 antigen binding unit and uses thereof
HK1137656B (en) Diagnosis and treatment of cancer using anti-ereg antibody